Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

3.07USD
18 Apr 2019
Change (% chg)

$0.05 (+1.66%)
Prev Close
$3.02
Open
$3.05
Day's High
$3.15
Day's Low
$2.97
Volume
6,004
Avg. Vol
6,849
52-wk High
$11.65
52-wk Low
$2.93

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $30.55
Shares Outstanding(Mil.): 9.95
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): -- 109.48 62.40
EPS (TTM): -1.67 -- --
ROI: -34.54 7.96 11.78
ROE: -36.65 8.11 12.61

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

22 Oct 2018

Earnings vs. Estimates